Taligen Therapeutics, Inc.: Series B $65M

Posted in I - Series B, Q - 1Q08, R - ROCKY MOUNTAIN, X - AMD, X - Asthma, X - Inflammation

Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.

Arriva Pharmaceuticals, Inc.: Series ? $6M

Posted in Q - 1Q08, R - WEST, X - Inflammation, X - Respiratory

Arriva Pharmaceuticals (Alameda, CA) a development stage biotechnology company focused anti-inflammatory therapies for treating respiratory diseases closed a $6M financing. Participants included Nordic Biotech and MPM Capital.

TyRx Pharma, Inc.: Series A $25M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Drug:Device Combo

TyRx Pharma (Monmouth Junction, NJ) a commercialization-stage developer of implantable drug-device combination products closed a $25M Series A financing. Participants include Clarus Ventures and Pappas Ventures.

PhaseRx, Inc.: Series A $19M

Posted in I - Series A, Q - 1Q08, R - NORTH WEST, X - siRNA

PhaseRx (Seattle, WA) an early-stage siRNA therapeutic company closed a $19M Series A financing. Participants include 5AM Ventures, Arch Venture Partners and Versant Ventures.

Cianna Medical, Inc.: Series A $9M

Posted in I - Series A, Q - 1Q08, R - WEST, X - Oncology

Cianna Medica (Aliso Viejo, CA) a brachytherapy medical device company focused on women’s health and dedicated to the innovative treatment of early-stage breast cancer closed a $9M Series A financing. Participants include BioLucent, Fog City Fund and Windamere Venture Partners.

Obalon Therapeutics, Inc.: Series A $7.7M

Posted in I - Series A, Q - 1Q08, R - WEST, XX - Stealth Mode

Obalon Therapeutics (San Diego, CA) a stealth mode drug startup closed on a $4.7M tranche of a $7.7M Series A financing. Participants include Domain Associates, Okapi Ventures and Phagia Technology Inc.

Adnavance Technologies, Inc.: Series B $3.6M

Posted in I - Series B, Q - 1Q08, R - INTERNATIONAL, X - Diagnostic, X - MRSA

Adnavance (Canada) developer of DNA detection molecular diagnostic tests for MRSA identification closed a $3.7M Series B financing. Participants include GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada.

Vaccinex, Inc.: Series B $25M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Inflammation, X - Oncology

Vaccinex (Rochester, NY) a research and development stage antibody platform company focused on oncology and inflammation closed a $25M Series B financing. Participants include Teva Pharmaceuticals, Pan Atlantic Bank & Trust, Biocon and Toronto Investment Group.

Affomix, Corp.: Series A $7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Microarray

Affomic (New Haven, CT) a development stage biotechnology company designing antibody microarrays closed a $7M Series A financing. Participants include Connecticut Innovations, Elm Street Ventures, and Four Seasons Ventures.

Nerites Corp.: Series A $5.7Mus

Posted in I - Series A, Q - 1Q08, R - MID WEST, X - Device (Coatings), X - Wound Healing

Nerites (Madison, WI) a development stage company foced on tissue repair products and coatings for medical device coatings closed a $5.7M series A financing. Participants include Venture Investors and Black Mountain Ventures.

« Previous Entries

to top of page...